# US 2015/0104464 A1 · Monoclonal antibody therapy for pancreas cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104464 A1
- Document ID: US20150104464A1
- Status: Published application
- Kind: A1
- Application number: 14/509,428
- Filed: 2014-10-08
- Published: 2015-04-16
- Earliest claimed: 2001-03-15
- Assignees: Precision Biologics, Inc.
- Applicants: Precision Biologics, Inc.
- Inventors: Myron Arlen; Kwong Tsang
- Web page: https://patentgrep.com/patent/US20150104464A1

## CPC

- C07K 16/303: {Liver or Pancreas}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 47/6859: {the tumour determinant being from liver or pancreas cancer cell}
- A61K 49/04: X-ray contrast preparations
- A61K 49/16: Antibodies; Immunoglobulins; Fragments thereof
- A61K 49/221: {characterised by the targeting agent or modifying agent linked to the acoustically-active agent}
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 35/00: Antineoplastic agents
- G01N 33/57525: of the liver or pancreas
- A61K 2039/505: {comprising antibodies}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2319/00: Fusion polypeptide
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method for detecting whether a subject has a pancreatic carcinoma comprising:
(a) providing a specimen from a subject being diagnosed for a pancreatic carcinoma,
(b) contacting said specimen with a monoclonal antibody 31.1, and
(c) detecting the presence of an antigen-antibody complex,
wherein the presence of an antigen-antibody complex indicates the presence of pancreatic cancer.

### Claim 22 (depends on 21)

The method of claim 21, wherein said antibody is reactive with pancreatic cancer cells, or is reactive with malignant cancer cells.

### Claim 23 (depends on 21)

The method of claim 21, wherein said antibody is a recombinant, chimerized, co-specific, or humanized antibody.

### Claim 24 (depends on 23)

The method of claim 23, wherein said chimerized antibody is expressed by a cell line deposited under ATCC Accession Number CRL-12316.

### Claim 25 (depends on 21)

The method of claim 21, wherein said antibody is selected from the group consisting of a single chain antibody, a F(ab) fragment, and a F(ab)2 fragment.

### Claim 26 (depends on 21)

The method of claim 21, wherein said specimen comprises tissue or cells.

### Claim 27 (depends on 21)

The method of claim 21, wherein the specimen is surgically obtained from the subject.

### Claim 28 (depends on 21)

The method of claim 21, wherein the light chain of said antibody is encoded by the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 3, or a humanized variant of SEQ ID NO: 1 or SEQ ID NO: 3.

### Claim 29 (depends on 21)

The method of claim 21, wherein the heavy chain of said antibody is encoded by the nucleotide sequence of SEQ ID NO: 4, SEQ ID NO: 6, or a humanized variant of SEQ ID NO: 4 or SEQ ID NO: 6.

### Claim 30 (depends on 21)

The method of claim 21, wherein said antibody or fragment is conjugated to a bioactive agent.

### Claim 31 (depends on 21)

The method of claim 21, wherein said antibody-antigen complex is detected by an assay selected from the group consisting of Western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), “sandwich” immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, and protein A immunoassays.

### Claim 32 (depends on 21)

The method of claim 21, wherein said method further comprises physical examination or a radiological study to detect the presence of pancreatic cancer.

### Claim 33 (depends on 32)

The method of claim 32, wherein said radiological study is a chest X-ray, computerized tomography, magnetic resonance imaging, or ultrasound.

### Claim 34 (depends on 21)

The method of claim 21, wherein said subject has recurrent or metastatic adenocarcinoma of the pancreas.

### Claim 35 (depends on 21)

The method of claim 21, wherein said subject has cancer or is at risk for cancer.

### Claim 36 (depends on 21)

The method of claim 21, wherein said antibody is affixed to a microtiter plate.

### Claim 37

An imaging method for detecting a pancreatic carcinoma antigen in a subject comprising
(a) contacting pancreatic cells with a labeled monoclonal antibody 31.1 or a fragment thereof; and
(b) detecting pancreatic cells that specifically binds to said labeled antibody or fragment, wherein said specific binding indicates the presence of pancreatic carcinoma cells that express said antigen.

### Claim 38

A method of killing cells carrying a pancreatic carcinoma associated antigen, comprising delivering to said cells an effective amount of 31.1 monoclonal antibody.
